OBJECTIVES: To estimate the financial implications of introducing Treprostinil to treatment of patients with pulmonary arterial hypertension NYHA class IV without response to pharmacological therapies in the budget of public health institutions in Mexico.

METHODS: A budget impact analysis was performed where two scenarios were considered, the current scenario in which the target population is treated with the standard therapy (diuretics, digitalis and vasodilators), on the other hand, the future scenario where these patients are treated with Treprostinil based in a market penetration rate of 2% in the first year and increases of 2% per annum over a 5-year horizon (2017-2021). Direct medical costs were considered, which are the drugs for each of the therapies included in the analysis. The target population was estimated based on the prevalence of pulmonary arterial hypertension NYHA class IV without response to pharmacological therapies in patients aged 16 to 65 years and affiliated with a public health institution. The costs and results are presented in pound sterling (£, 2017) and the epidemiology data used was obtained from institutional sources in the country and from a panel of experts (Delphi method).

RESULTS: The average annual cost per patient was £ 68,167.70 for treatment with Treprostinil . Based in the penetration rate, the time horizon and the population eligible for treatment (280 in 2017, 284 in 2018, 287 in 2019, 291 in 2020 and 294 in 2021), the estimated additional average consumption is £ 1,183,990.00. Represents 0.0187% of the total budget allocated to medicines, all within the 5 years’ time horizon.

CONCLUSIONS: The introduction of Treprostinil into the public health sector in Mexico does not represent a significant financial impact of mexican's budget.